Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...

Headquartered in Tarrytown, New York, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,150.00.

Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders might be concerned after seeing the share price drop ...

On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

On Wednesday, Regeneron Pharmaceuticals Inc (REGN) stock saw a decline, ending the day at $941.39 which represents a decrease of $-20.95 or -2.18% from the prior close of $962.34. The stock opened at ...

Robert W. Baird analyst Brian Skorney maintained a Hold rating on Regeneron (REGN – Research Report) on October 22 and set a price target ...

Two billion dollars in investments. 4,500 employees. Regeneron has grown into a major economic engine — and it's now ...

REGNERON'S eighth annual “Day for Doing Good” was marked in Limerick and all over the world. It is a global volunteerism ...

Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in ...